Decreased levels of urinary liver-type fatty acid-binding protein after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study

被引：3

作者：

Hikasa, Shinichi ^{[1
]}

Shimabukuro, Shota ^{[1
]}

Hideta, Kyoko ^{[1
]}

Nishida, Sakurako ^{[1
]}

Higasa, Satoshi ^{[2
]}

Sawada, Akihiro ^{[2
]}

Tokugawa, Tazuko ^{[2
]}

Tanaka, Kuniyoshi ^{[1
]}

Yanai, Mina ^{[1
]}

Kimura, Takeshi ^{[1
]}

机构：

[1] Hosp Hyogo, Dept Pharm, Coll Med, Nishinomiya, Hyogo, Japan

[2] Hyogo Coll Med, Dept Internal Med, Div Hematol, Nishinomiya, Hyogo, Japan

来源：

INTERNATIONAL JOURNAL OF STD & AIDS | 2019年 / 30卷 / 13期

关键词：

Tenofovir disoproxil fumarate; tenofovir alafenamide; liver-type fatty acid-binding protein; HIV; estimated glomerular filtration rate; beta; 2; microglobulin; protein-to-creatinine ratio; HIV-INFECTED PATIENTS; CARDIOVASCULAR EVENTS; KIDNEY INJURY; DOUBLE-BLIND; SINGLE-ARM; EMTRICITABINE; ELVITEGRAVIR; COBICISTAT; MORTALITY; EFFICACY;

D O I：

10.1177/0956462419873772

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A single-center, prospective, observational study was conducted between September 2016 and August 2018 in 33 HIV-positive Japanese patients who switched antiretroviral drug regimens from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF). The study assessed changes in urinary levels of liver-type fatty acid-binding protein (L-FABP) after switching from TDF to TAF and determined the potential of renal parameters to predict improvement in estimated glomerular filtration rate (eGFR). Median urinary levels of L-FABP were found to be 2.0, 1.4, and 1.3 mu g/g creatinine before, at 6 months, and at 12 months after switching to TAF, respectively. The urinary levels of L-FABP, beta 2 microglobulin (beta 2MG), and eGFR and the protein-to-creatinine ratio (PCR) were not significantly related to the annual change in eGFR after switching from TDF to TAF. Our results demonstrate a significant decrease in urinary levels of L-FABP after switching from TDF to TAF. However, neither urinary L-FABP, beta 2MG, PCR, nor eGFR predicted the annual change in eGFR after the change in medication.

引用

页码：1311 / 1317

页数：7

共 32 条

[1] The role of tenofovir alafenamide in future HIV management [J].

Antela, A. ;

Aguiar, C. ;

Compston, J. ;

Hendry, B. M. ;

Boffito, M. ;

Mallon, P. ;

Pourcher-Martinez, V. ;

Di Perri, G. .

HIV MEDICINE, 2016, 17 :4-16

[2] Predictive Effects of Urinary Liver-Type Fatty Acid-Binding Protein for Deteriorating Renal Function and Incidence of Cardiovascular Disease in Type 2 Diabetic Patients Without Advanced Nephropathy [J].

Araki, Shin-ichi ;

Haneda, Masakazu ;

Koya, Daisuke ;

Sugaya, Takeshi ;

Isshiki, Keiji ;

Kume, Shinji ;

Kashiwagi, Atsunori ;

Uzu, Takashi ;

Maegawa, Hiroshi .

DIABETES CARE, 2013, 36 (05) :1248-1253

[3]

Arribas JR, 2017, JAIDS-J ACQ IMM DEF, V75, P211, DOI [10.1097/QAI.0000000000001350, 10.1097/qai.0000000000001350]

[4] Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy [J].

Bandera, Alessandra ;

Gori, Andrea ;

Sabbatini, Francesca ;

Madeddu, Giordano ;

Bonora, Stefano ;

Libertone, Raffaella ;

Mastroianni, Claudio ;

Bonfanti, Paolo ;

Monforte, Antonella d'Arminio ;

Cozzi-Lepri, Alessandro .

PLOS ONE, 2015, 10 (05)

[5] Race and Other Risk Factors for Incident Proteinuria in a National Cohort of HIV-Infected Veterans [J].

Banerjee, Tanushree ;

Scherzer, Rebecca ;

Powe, Neil R. ;

Steffick, Diane ;

Shahinian, Vahakn ;

Saran, Rajiv ;

Pavkov, Meda E. ;

Saydah, Sharon ;

Shlipak, Michael G. .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 67 (02) :145-152

[6] Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial [J].

Gallant, Joel E. ;

Daar, Eric S. ;

Raffi, Francois ;

Brinson, Cynthia ;

Ruane, Peter ;

DeJesus, Edwin ;

Johnson, Margaret ;

Clumeck, Nathan ;

Osiyemi, Olayemi ;

Ward, Doug ;

Morales-Ramirez, Javier ;

Yan, Mingjin ;

Abram, Michael E. ;

Plummer, Andrew ;

Cheng, Andrew K. ;

Rhee, Martin S. .

LANCET HIV, 2016, 3 (04) :E158-E165

[7] Kidney function and the risk of cardiovascular events in HIV-1-infected patients [J].

George, Elizabeth ;

Lucas, Gregory M. ;

Nadkarni, Girish N. ;

Fine, Derek M. ;

Moore, Richard ;

Atta, Mohamed G. .

AIDS, 2010, 24 (03) :387-394

[8] Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [J].

Go, AS ;

Chertow, GM ;

Fan, DJ ;

McCulloch, CE ;

Hsu, CY .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (13) :1296-1305

[9] Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials [J].

Hagins, D. ;

Orkin, C. ;

Daar, E. S. ;

Mills, A. ;

Brinson, C. ;

DeJesus, E. ;

Post, F. A. ;

Morales-Ramirez, J. ;

Thompson, M. ;

Osiyemi, O. ;

Rashbaum, B. ;

Stellbrink, H-J ;

Martorell, C. ;

Liu, H. ;

Liu, Y-P ;

Porter, D. ;

Collins, S. E. ;

SenGupta, D. ;

Das, M. .

HIV MEDICINE, 2018, 19 (10) :724-733

[10] Utility of urinary liver-type fatty acid-binding protein as a predictor of renal dysfunction in Japanese patients with HIV receiving tenofovir disoproxil fumarate with low urinary 2 microglobulin levels: a retrospective observational study [J].

Hikasa, Shinichi ;

Shimabukuro, Shota ;

Hideta, Kyoko ;

Higasa, Satoshi ;

Sawada, Akihiro ;

Tokugawa, Tazuko ;

Tanaka, Kuniyoshi ;

Yanai, Mina ;

Kimura, Takeshi .

JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES, 2019, 5 (1)

← 1 2 3 4 →